Table 3.
The main features of 24 included studies in prognostic meta-analysis.
| id | ethnicity | age | sample size | male/female | specimen | cancer | median follow-up time(month) | outcome | HR with 95% CI | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| Jung K 2004 | Caucasian | NA | 115 | 115/0 | serum | prostate Cancer | 36.1 | OS | 7.57[2.65–21.6] | 8 |
| Brown J 2005 | Caucasian | 73 | 203 | 203/0 | urine | prostate Cancer | NA | OS | 2.40[1.73–3.33] | 8 |
| Coleman R 2005 | Caucasian | 57.5 | 742 | 742 | urine | breast cancer | 27.2 | OS | 3.03[2.04–4.51] | 8 |
| Coleman R 2005 | Caucasian | 72 | 435 | 435/0 | urine | prostate Cancer | 17.1 | OS | 4.10[2.81–5.97] | 8 |
| Coleman R 2005 | Caucasian | 63 | 259 | 259 | urine | NSCLC | 6.3 | OS | 2.27[1.49–3.47] | 8 |
| Coleman R 2005 | Caucasian | 62 | 343 | 343 | urine | multiple myeloma | 40.4 | OS | 2.40[0.76–7.61] | 8 |
| Cook R 2006 | Caucasian | 71.7 | 643 | 643/0 | urine | prostate Cancer | NA | OS | 1.92[1.56–2.36] | 7 |
| Lipton A 2007 | Asian/Caucasian/African | 58.2 | 328 | 2/326 | urine | breast cancer | NA | OS | 2.20[1.42–3.41] | 8 |
| Hirsh V 2008 | Asian/Caucasian/African | NA | 144 | 94/50 | urine | NSCLC | NA | OS | 1.26[0.89–1.80] | 7 |
| Lipton A 2008 | Asian/Caucasian/African | NA | NA | NA | urine | prostate Cancer | NA | OS | 2.44[1.69–3.45] | 8 |
| Rajpar S 2010 | Caucasian | 66 | 94 | 94/0 | urine | prostate Cancer | 30 | OS | 3.01[1.77–5.12] | 8 |
| Zhao X 2010 | Asian | NA | 60 | 0/60 | serum | breast cancer | 21.8 | PFS | 1.05[1.02–1.08] | 7 |
| Jung K 2011 | Caucasian | 68 | 52 | 52/0 | serum | prostate Cancer | 52.5 | OS | 2.72[1.36–5.46] | 8 |
| Som A 2012 | Caucasian/African | 62 | 67 | 67/0 | urine | prostate Cancer | NA | OS | 1.47[0.95–2.26] | 6 |
| Som A 2012 | Caucasian/African | 60 | 125 | 125/0 | urine | prostate Cancer | NA | OS | 1.62[1.15–2.29] | 6 |
| Barnadas A 2014 | Caucasian | 59.8 | 234 | 0/234 | urine | breast cancer | NA | OS | 2.19[1.32–3.62] | 7 |
| Clemons M 2014 | Caucasian | 59 | 129 | 0/129 | urine | breast cancer | NA | OS | 2.42[1.31–4.48] | 9 |
| Lara P 2014 | Asian/Caucasian/African | 69 | 778 | 778/0 | serum | prostate Cancer | NA | OS | 1.40[1.27–1.54] | 6 |
| Pan T 2014 | Asian | 58 | 30 | 19,11 | urine | lung cancer and gastrointestinal tumor | NA | OS | 5.39[1.3–22.37] | 7 |
| Fizazi K 2015 | Caucasian | NA | NA | NA | urine | prostate Cancer | 20 | OS | 2.28[1.99–2.61] | 8 |
| Ferreira A 2016 | Caucasian | 63 | 71 | 71 | urine | breast cancer | 28.4 | OS | 1.59[0.84–3.00] | 8 |
| Lipton A 2016 | Asian/Caucasian/African | NA | NA | NA | urine | lung Cancer | NA | OS | 1.83[1.44–2.33] | 8 |
| Honda Y 2017 | Asian | 68 | 46 | 40/6 | serum | hepatocellular carcinoma | 11.5 | OS | 2.13[1.02–4.44] | 8 |
| Shizuku M 2020 | Asian | 66 | NA | NA | urine | breast cancer | 20 | OS | 2.07[0.85–5.31] | 7 |
Abbreviation: 95% CI, 95% confidence interval; HR, hazard ratio; NOS, Newcastle-Ottawa Scale; OS, overall survival; PFS, progression-free survival.